{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:46:52Z","timestamp":1791726412881,"version":"4.3.4"},"reference-count":20,"publisher":"SAABRON PRESS","issue":"3","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The gut microbiome has emerged as a critical factor influencing cancer progression, treatment response, and complications in hematology and oncology. Fecal microbiota transfer (FMT) is being explored as a novel biotherapeutic strategy, yet the knowledge and attitudes of healthcare professionals towards its clinical use remain poorly defined. We conducted an international survey of 152 healthcare professionals, including hematologists, oncologists, transplant specialists, and others. Most respondents were affiliated with academic centers (66.0%) and practiced primarily in hematology (48.0%) or transplantation (34.0%). Awareness of the microbiome\u2019s clinical relevance was widespread, but perceptions of microbiome profiling and FMT remained cautious. One-third of participants were in favor of routine microbiome profiling, while half considered it promising but still investigational. Direct clinical experience with FMT was limited: only 20.4% had prescribed it and 14.5% had referred patients. Nonetheless, over half indicated they would consider adopting FMT in the near future. The main reported barriers to broader use included limited regulatory approval (63.8%), logistical or supply challenges (57.9%), and physician skepticism or lack of knowledge (51.3%). Despite these challenges, more than 70% of respondents expressed strong interest in further education, standardized guidelines, and training opportunities to support safe and effective implementation. This survey highlights a strong enthusiasm regarding microbiome-based interventions in cancer and transplantation care. While current clinical use remains limited, healthcare professionals recognize the therapeutic potential of FMT and call for structured education, multidisciplinary collaboration, and clear regulatory frameworks to enable its integration into routine practice.<\/jats:p>","DOI":"10.46989\/001c.166241","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:30:53Z","timestamp":1789583453000},"source":"Crossref","is-referenced-by-count":0,"title":["Healthcare professionals\u2019 knowledge and attitudes toward the microbiome and fecal microbiotherapy or microbiota transfer in hematology and oncology: an international survey"],"prefix":"10.46989","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-045X","authenticated-orcid":true,"given":"Marion","family":"Larue","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9; Centre de Recherche Saint-Antoine INSERM UMRs938; Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Battipaglia","sequence":"additional","affiliation":[{"name":"Hematology Department, Federico II University, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Poeck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany"},{"name":"Leibniz Institute for Immunotherapy (LIT), Regensburg, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Masetti","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria di Bologna","department":["Pediatric Unit"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stein-Thoeringer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Departament de Medicina, Universitat de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Hematology and Bone marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[{"name":"University Hospital Centre Rijeka and School of Medicine, University of Rijeka, Rijeka, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 ; Centre de Recherche Saint-Antoine INSERM UMRs938; Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 ; Centre de Recherche Saint-Antoine INSERM UMRs938; Service d'H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire, H\u00f4pital Saint Antoine, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.2024025366","article-title":"Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy","volume":"145","author":"R. Prasad","year":"2025","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","article-title":"Key determinants of success in fecal microbiota transplantation: from microbiome to clinic","volume":"31","author":"S. Porcari","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41409-025-02779-9","article-title":"Microbiotherapy and fecal microbiota transplantation in hematology-oncology: a European clinical perspective","volume":"61","author":"F. Malard","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2024.05.038","article-title":"Real-world effectiveness of fecal microbiota transplantation for first or second Clostridioides difficile infection","volume":"23","author":"S. E. Paaske","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1053\/j.gastro.2020.07.045","article-title":"Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection","volume":"159","author":"J. R. Allegretti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41409-023-02115-z","article-title":"Current use of fecal microbiota transfer in patients with hematologic diseases","volume":"58","author":"G. Battipaglia","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2024015571","article-title":"Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial","volume":"9","author":"F. Malard","year":"2025","journal-title":"Blood Adv"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bjh.16204","article-title":"Gut microbiota alteration during allogeneic haematopoietic cell transplantation: what can we do?","volume":"188","author":"F. Malard","year":"2020","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"102111","DOI":"10.1016\/j.eclinm.2023.102111","article-title":"Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a phase 2 trial","volume":"62","author":"F. Malard","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3324\/haematol.2018.198549","article-title":"Fecal microbiota transplantation before or after allogeneic transplantation in patients with hematologic malignancies carrying multidrug-resistant bacteria","volume":"104","author":"G. Battipaglia","year":"2019","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41385-020-00365-4","article-title":"Introduction to host microbiome symbiosis in health and disease","volume":"14","author":"F. Malard","year":"2021","journal-title":"Mucosal Immunol"},{"issue":"12","key":"ref12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41579-019-0271-9","article-title":"The future of faecal transplants","volume":"17","author":"E. M. Giles","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"V. Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"M. Smith","year":"2022","journal-title":"Nat Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1900623","article-title":"Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation","volume":"382","author":"J. U. Peled","year":"2020","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/PPO.0000000000000645","article-title":"The microbiome and its impact on allogeneic hematopoietic cell transplantation","volume":"29","author":"F. Malard","year":"2023","journal-title":"Cancer J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood.2020009963","article-title":"Let's reconstitute microbiota diversity","volume":"137","author":"F. Malard","year":"2021","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1172\/JCI125797","article-title":"The gut microbiota and graft-versus-host disease","volume":"129","author":"D. N. Fredricks","year":"2019","journal-title":"J Clin Invest"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e776","DOI":"10.1016\/S2352-3026(22)00223-X","article-title":"Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice","volume":"9","author":"F. Malard","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","article-title":"A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","volume":"29","author":"C. K. Stein-Thoeringer","year":"2023","journal-title":"Nat Med"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/166241-healthcare-professionals-knowledge-and-attitudes-toward-the-microbiome-and-fecal-microbiotherapy-or-microbiota-transfer-in-hematology-and-oncology-a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:36:31Z","timestamp":1791725791000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/166241-healthcare-professionals-knowledge-and-attitudes-toward-the-microbiome-and-fecal-microbiotherapy-or-microbiota-transfer-in-hematology-and-oncology-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.166241","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}